MyMeds&Me announce collaboration with Oracle Health Sciences

MyMeds&Me announce collaboration with Oracle Health Sciences


Oracle Argus Safety customers gain access to the Reportum solution to further streamline and strengthen their Pharmacovigilance operations.

MyMeds&Me, a leading SaaS provider of web-based adverse event and product quality capture solutions for life sciences, today announced their collaboration with Oracle Health Sciences to provide the Reportum solution to Oracle Argus safety customers.

This collaboration allows access to the innovative Reportum solution providing a standardised method of capturing complete Adverse Event data at source, from all reporter types. The Reportum solution provides simple, web-based, user-friendly safety data capture at initial reporter interaction and supports direct reporting by consumers – streamlining what is often a paper-based activity that generates duplicate data entry processes, call centres – often dealing with high volumes of contacts with varying levels of experience and healthcare professionals.

For Oracle customers, the Oracle Argus pharmacovigilance platform will provide the hub for all safety and product quality data captured via the Reportum solution. They will be able to review, manage, analyse and report all safety and product quality data consistently, irrespective of reporting route.

This combined solution will enable life science companies with Adverse Event obligations to:

  • Increase pharmacovigilance efficiency and reduce cost
  • Deliver complete, cleaner data to regulators, faster
  • Improve understanding of benefit risk profiles for pharmaceutical products

Request More Information

To find out more or request a demo fill in the details below:

By submitting your information, you are consenting to receive communications from MyMeds&Me. You may at any time 'opt out' of receiving these marketing communications by emailing


We use analytical cookies that need your permission. For more details and advanced options view our Cookies Policy.